Abstract
BackgroundCurrent approach for diabetes treatment remained several adverse events varied from gastrointestinal to life-threatening symptoms. Regenerative therapy regarding Edmonton protocol has been facing serious limitations involving protocol efficiency and safety. This led to the study for alternative insulin-producing cell (IPC) resource and transplantation platform. In this study, evaluation of encapsulated human dental pulp-derived stem cell (hDPSC)-derived IPCs by alginate (ALG) and pluronic F127-coated alginate (ALGPA) was performed.ResultsThe results showed that ALG and ALGPA preserved hDPSC viability and allowed glucose and insulin diffusion in and out. ALG and ALGPA-encapsulated hDPSC-derived IPCs maintained viability for at least 336 h and sustained pancreatic endoderm marker (NGN3), pancreatic islet markers (NKX6.1, MAF-A, ISL-1, GLUT-2 and INSULIN), and intracellular pro-insulin and insulin expressions for at least 14 days. Functional analysis revealed a glucose-responsive C-peptide secretion of ALG- and ALGPA-encapsulated hDPSC-derived IPCs at 14 days post-encapsulation.ConclusionALG and ALGPA encapsulations efficiently preserved the viability and functionality of hDPSC-derived IPCs in vitro and could be the potential transplantation platform for further clinical application.
Highlights
Current approach for diabetes treatment remained several adverse events varied from gastrointestinal to life-threatening symptoms
Dental tissue-derived mesenchymal stem cells (MSCs) can be proposed as an alternative source, in vitro generation of insulin-producing cell (IPC) was firstly achieved by using MSCs isolated from Stem cells from human exfoliated deciduous teeth (SHED) or stem cell from human exfoliated deciduous teeth [12]
At day 0 there is no significant difference on beads diameter produced from all different size of needle between alginate (ALG) and pluronic F127 coated alginate (ALGPA) encapsulation
Summary
Current approach for diabetes treatment remained several adverse events varied from gastrointestinal to life-threatening symptoms. Regenerative therapy regarding Edmonton protocol has been facing serious limitations involving protocol efficiency and safety This led to the study for alternative insulin-producing cell (IPC) resource and transplantation platform. Derivation from mouse and human embryonic stem cells (ESCs) has been reported [7, 8], the ethical and tumorigenicity issue might hamper for the clinical application [9]. To address this problem, current plethora of studies are mainly focused on mesenchymal stem cells (MSCs) [10]. The advantages of hDPSC have been reported by several investigators i.e. the multilineage differentiation potential, the capacity for autologous and allogenic transplantation [16], the abundance in source and less ethical issue both in research and clinical translation [17]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
